Detail akcie Immunome Rg online

Business Summary: Immunome, Inc. is a clinical-stage targeted oncology company, which is focused on developing first-in-class and targeted therapies designed to improve outcomes for cancer patients. The Company is engaged in advancing an innovative portfolio of therapeutics in the design, development, and commercialization of targeted cancer therapies, including antibody-drug conjugate therapies (ADCs). Its advanced pipeline programs are varegacestat, a gamma secretase inhibitor which is in a Phase III trial for the treatment of desmoid tumors; IM-1021, an ROR1-targeted ADC which is in a Phase I trial, and IM-3050, a FAP-targeted radioligand. The Company's pipeline also includes IM-1617, IM-1335, and IM-1340, all of which are preclinical ADCs pursuing undisclosed targets with expression in multiple solid tumors. IM-1617 is a potential first-in-class ADC that targets an undisclosed receptor that is expressed in a range of solid tumors, including colorectal cancer and ovarian cancers.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Immunome Inc revenues increased 10% to $6.9M. Net loss decreased 33% to $142.5M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects PHARMACEUTICAL PREPARATIONS segment loss decrease of 73% to $60.1M, United States segment loss decrease of 73% to $60.1M.